Sitagliptin/Metformin FDC

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC, ADIUM

Conditions

BioequivalanceBioequivalenceType 2 Diabetes Mellitus

Phase 4

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

CompletedNCT00993187

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2010-05-04End: 2013-10-29Updated: 2018-08-22

Unknown Phase

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.

CompletedNCT07763912

ADIUMBioequivalence

Start: 2025-11-24End: 2025-12-05Updated: 2026-08-14

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.

CompletedNCT07763899

ADIUMBioequivalance

Start: 2025-11-19End: 2025-11-30Updated: 2026-08-14

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.

CompletedNCT07763964

ADIUMBioequivalance

Start: 2025-12-08End: 2025-12-19Updated: 2026-08-14

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.

CompletedNCT07763951

ADIUMBioequivalance

Start: 2025-12-03End: 2025-12-14Updated: 2026-08-14